Back to search

National and Kapodistrian University of Athens

Επίδραση του αυξητικού παράγοντα του αγγειακού ενδοθηλίου (VEGF) στους υποπληθυσμούς των λεμφοκυττάρων στον καρκίνο ωοθηκών

Abstract

dc:description

INTRODUCTIONEpithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies and the fourth most common cause of cancer-related deaths among women. Recent data suggest that VEGF contributes to tumor growth not only by promoting angiogenesis but also by an indirect mechanism of regulation of T cells involved in the immune response against the tumor. T cells are pivotal in the induction and progression of the anti-tumor immune reaction in many types of cancer, including ovarian carcinomas and cancer patients demonstrate impaired T-cell functions. In previous studies of the Department of Clinical Therapeutics of university of Athens, has been demonstrated that the levels of VEGF in the ascitic fluid was an independent adverse prognostic factor in a cohort of 65 patients with advanced ovarian cancer and were inversely correlated with immunologically important T-cell subpopulations, such as CD3+CD56+ NK-like T cells. These results were indicative of an additional immunosuppressive function exerted by this factor. Nevertheless, the direct effect of VEGF on T cells as well as the mechanisms underlying such actions has not been studied yet.AIMThe aim of the present thesis is to study the possible direct effect of vascular endothelial growth factor (VEGF) on T cells subpopulations of ovarian cancer patients.MATERIALS AND METHODSAscitic fluids and peripheral blood samples were collected in heparinized tubes from over 25 patients who had undergone surgery in the Ά Department of Obstetrics and Gynecology of university of Athens and their histological exam reported epithelial ovarian cancer. In the publication of the study were included samples from 15 ovarian cancer patients and peripheral blood samples from 10 healthy donors. The study protocol had appropriate IRB approval and all subjects gave their informed consent for the collection of the samples. T cells isolated from the biological samples were expanded in cultures for 14 days, with or without VEGF and the number of viable T cells were counted. The expression of VEGF receptors was assayed by flow cytometry, immunocytochemistry and Western blotting Cultured T cells were also tested for their cytotoxic activity in a standard 4-hr 51Cr-release assay, and to assess the ability of activated T cells to secrete VEGF, levels in culture supernatants were measured by enzyme linked immunosorbent assay.RESULTS-DISCUSSIONDue to the size of the study and the clinical significance of the results it was decided to separate the publication of the results. The first publication regards to the effect of VEGF on lymphocytes isolated from the peripheral blood of patients with ovarian cancer and healthy donors and the second one regards to the effect of VEGF on lymphocytes isolated from ascetic fluid of patients with ovarian cancer.The results regarding the effect of vascular endothelial growth factor on lymphocytes isolated from peripheral blood of ovarian cancer patients and healthy donors were published in February 2012 in International Journal of Cancer. Briefly, we demonstrated a significant inhibitory effect of VEGF on the proliferation of T cells derived from peripheral blood lymphocytes. This effect was time- and dose-dependent and was similar among the cancer patient and healthy donor-derived cell cultures. CD3+ T cells expressed VEGFR-2 on their surface upon activation. This was confirmed by flow cytometry, immunocytochemistry and western blotting analysis. We also showed that VEGF suppresses T cell proliferation through VEGFR-2, as the addition of anti-VEGFR-2 mAb fully restored the VEGF-induced suppression of T cell proliferation both in cancer patient and healthy donor-derived cell cultures. Furthermore, we showed that VEGF significantly reduced the cytotoxic activity of T cells against K562 and Daudi-target cells. Moreover, we demonstrated that activated T cells have the ability to secrete VEGF in their culture environment. Overall, this study showed that T cells secret VEGF and expresses VEGFR-2 upon activation and VEGF directly suppresses T cell activation via VEGF receptor type 2.We believe that this publication provided the research community with the insight of a mechanism of T cell suppression in the context of excessive production of VEGF, such as malignant conditions. We show that this suppression is mediated through the expression of VEGFR-2 on T cell surface. The translational consequence of the above is that VEGF may be a marker not only for angiogenesis but it may also play a direct suppressive role on T cells and more specifically on cells of the immune system that are involved in fighting cancer. The production of low amounts of VEGF by T cells may contribute to local angiogenesis under physiological conditions. These results underline the pleiotropic actions of VEGF in carcinogenesis and cancer progression and strengthen its prognostic importance in ovarian cancer. They are clinically relevant particularly after recent reports suggesting a benefit by the addition of an anti-VEGF monoclonal antibody to chemotherapy for advanced ovarian cancer.The results regarding the effect of vascular endothelial growth factor on lymphocytes isolated from ascitis of ovarian cancer patients were published in November 2012 in British Journal of Cancer. Briefly, we demonstrated that the addition of VEGF in cultures significantly reduced the number and proliferation rate of T cells. This effect was time- and dose-dependent. CD3+ T cells expressed VEGFR-2 on their surface upon activation. This was confirmed by flow cytometry, immunocytochemistry and western blotting analysis. We also showed that VEGF suppresses T cell proliferation through VEGFR-2, as the addition of anti-VEGFR-2 mAb fully restored the VEGF-induced suppression of T cell proliferation. Furthermore, we showed that VEGF significantly reduced the cytotoxic activity of T cells against K562 and Daudi-target cells and against autologous cancer cells isolated from the ascetic fluid of the cancer patients. Moreover, we demonstrated that activated T cells have the ability to secrete VEGF in their culture environment. In summary, this study showed that T cells isolated from the ascites of ovarian cancer patients secret VEGF and expresses VEGFR-2 upon activation and VEGF directly suppresses T cell activation via VEGF receptor type 2. This publication confirmed the findings of the previous one and provided the research community with new knowledge of a mechanism of T cell suppression in the context of excessive production of VEGF, such as ascetic fluid of ovarian cancer patients. There is importance to mention that suppressive VEGF levels were similar to those measured in the ascites in this study as well as in a previous larger cohort of advanced ovarian cancer patients of Department of Clinical Therapeutics. It is also of importance to stress here, that the action of T cells against autologous cancer cells is a major feature of this study compared with our previous publication. In summary, we have demonstrated for the first time that T lymphocytes derived from ovarian cancer patients’ ascites secrete VEGF and express VEGFR-2 on their surface in response to their activation. This in turn, promotes the suppression of activated T cells by the VEGF produced by the tumour, thus suggesting an immunosuppressive effect. These findings may have clinical relevance, particularly after recent results suggesting a benefit by the addition of the anti-VEGF monoclonal antibody, bevacizumab, to chemotherapy for advanced ovarian cancer. The rationale is that anti-VEGF and/or VEGFR-2 therapies may target not only angiogenesis but also tumor escape from immune surveillance. If this is true, the degree of the effect of VEGF on the immune system may be used to select patients likely to benefit from such approaches.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ziogas, Apostolos
  • Ζιώγας, Απόστολος

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40615

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ziogas, Apostolos; Ζιώγας, Απόστολος. Επίδραση του αυξητικού παράγοντα του αγγειακού ενδοθηλίου (VEGF) στους υποπληθυσμούς των λεμφοκυττάρων στον καρκίνο ωοθηκών. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/40615